Korean J Gastroenterol.
1999 Jun;33(6):749-756.
An Effectiveness and Safety of Itopride versus Cisapride in Functional Dyspepsia
Abstract
-
BACKGROUND/AIMS: Itopride, a new gastroprokinetic benzamide derivative, stimulates gastric motility through both anti-dopaminergic and anti-acetylcholinesterase actions. The aim of this study was to compare the effectiveness and safety of itopride with those of cisapride in functional dyspepsia
METHODS
Eighty-four patients (46 patients in itopride group, 38 patients in cisapride group) with symptoms of functional dyspepsia were assigned to a prospective randomized parallel comparison of 50 mg of itopride t.i.d. or 5 mg of cisapride t.i.d. for 4 weeks. Symptom assessment was performed in each patient before and 2 and 4 weeks after beginning treament. Laboratory study were performed in each patient before and after treatment.
RESULTS
In both itopride and cisapride groups, average symptom number, total symptom score and symptom severity significantly decreased 2 and 4 weeks after treatment. The effectiveness for global evaluation was not different in both group. No serious adverse effects were reported after administeration of either itopride or cisapride. However, 3 patients in itopride group showed mild and transient adverse effects, while 9 patients in cisapride group re vealed mostly moderate adverse effects.
CONCLUSIONS
Itopride is as effective as cisapride for func tional dyspepsia without significant side effects and less active than cisapride in lower gastrointestinatract.